Published in Br J Cancer on December 17, 2015
Liver transplantation for small hepatocellular carcinoma. Hepatobiliary Surg Nutr (2016) 0.75
Surgery for small liver cancers. Semin Surg Oncol (1993) 3.00
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology (2003) 2.05
Ultrasound-guided radiofrequency thermal ablation of liver tumors: percutaneous, laparoscopic, and open surgical approaches. J Gastrointest Surg (2002) 1.84
Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol (2004) 1.83
Transfusion criteria for fresh frozen plasma in liver resection: a 3 + 3 cohort expansion study. Arch Surg (2011) 1.50
Des-gamma-carboxy prothrombin identified by P-11 and P-16 antibodies reflects prognosis for patients with hepatocellular carcinoma. J Gastroenterol Hepatol (2013) 1.49
Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg (1999) 1.42
Factors correlated with portal venous invasion by hepatocellular carcinoma: univariate and multivariate analyses of 232 resected cases without preoperative treatments. Cancer (1996) 1.36
The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol (2007) 1.30
Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer (1994) 1.16
New Pathologic Stratification of Microvascular Invasion in Hepatocellular Carcinoma: Predicting Prognosis After Living-donor Liver Transplantation. Transplantation (2015) 0.97
Criteria for drain removal following liver resection. Br J Surg (2012) 0.96
Early hepatocellular carcinoma: pathology, imaging, and therapy. Ann Surg Oncol (2008) 0.93
Novel des-γ-carboxy prothrombin in serum for the diagnosis of hepatocellular carcinoma. J Gastroenterol Hepatol (2013) 0.89
Outcomes and predictors of microvascular invasion of solitary hepatocellular carcinoma. Hepatol Res (2013) 0.87
Evaluation of the effect of sorafenib using serum NX-des-γ-carboxyprothrombin in patients with hepatocellular carcinoma. Hepatol Res (2013) 0.86
Ablation for hepatocellular carcinoma: validating the 3-cm breakpoint. Ann Surg Oncol (2013) 0.86
Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative des-gamma-carboxy prothrombin value. Transplant Proc (2005) 0.85
Des-γ-carboxy prothrombin ratio measured by P-11 and P-16 antibodies is a novel biomarker for hepatocellular carcinoma. Cancer Sci (2013) 0.85
Novel method to measure serum levels of des-gamma-carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: a preliminary report. Cancer Sci (2012) 0.82
NX-PVKA levels before and after hepatectomy of hepatocellular carcinoma as predictors of patient survival: a preliminary evaluation of an improved assay for PIVKA-II. Anticancer Res (2013) 0.81
Gene-expression phenotypes for vascular invasiveness of hepatocellular carcinomas. Surgery (2009) 0.80
Frequency of and predictive factors for vascular invasion after radiofrequency ablation for hepatocellular carcinoma. PLoS One (2014) 0.80
Validation of biological and clinical outcome between with and without thoracotomy in liver resection: a matched cohort study. World J Surg (2012) 0.80
NX-DCP as a novel biomarker would be related to liver function in cirrhotic patients with hepatocellular carcinoma. Eur J Gastroenterol Hepatol (2013) 0.78